James Sullivan
Director Técnico/Científico/I+D en ENGENE HOLDINGS INC. .
Cargos activos de James Sullivan
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ENGENE HOLDINGS INC. | Director Técnico/Científico/I+D | 01/11/2023 | - |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Director Técnico/Científico/I+D | 01/02/2022 | - |
Historial de carrera de James Sullivan
Antiguos cargos conocidos de James Sullivan.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| TRANSLATE BIO, INC. | Corporate Officer/Principal | 01/01/2021 | 01/02/2022 |
| SANA BIOTECHNOLOGY, INC. | Director/Miembro de la Junta | 01/08/2019 | 01/01/2021 |
| Corporate Officer/Principal | 01/08/2019 | 01/01/2021 |
Formación de James Sullivan.
| Boston College | Undergraduate Degree |
| University College Dublin | Graduate Degree |
| Boston University | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Canadá | 3 |
| Irlanda | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| ENGENE HOLDINGS INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- James Sullivan
- Experiencia
